iSpecimen

iSpecimen Long-term Debt

The Long-Term Debt of iSpecimen (ISPC) as of Nov 5, 2026 is 3.42 M USD. In the previous year, Long-Term Debt was 178,899.00 USD — a change of 1,813.16% (higher).

Long-term Debt

3.42 MUSD

YoY

1,813.16%

Last updated:

Long-Term Debt of iSpecimen is 2021 3.42 M USD. Long-Term Debt of iSpecimen was 2020 178,899.00 USD. It decreases by 1,813.16% higher compared to the previous year.

The iSpecimen Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2020
178,899.00 USD
Jan 1, 2021
3.42 M USD
The iSpecimen Long-term Debt history
YEARLong-term DebtYoY
3.42 MUSD+1,813.16%
178,899.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

iSpecimen Stock analysis

What does iSpecimen do? iSpecimen, Inc. generates revenue through its iSpecimen Marketplace platform, which connects healthcare providers with biospecimens to researchers in biopharmaceutical, in vitro diagnostic (IVD), and government/academic sectors. The platform consolidates biospecimen procurement by offering a single online marketplace where healthcare supply partners provide de-identified healthcare data, enabling researchers to search, manage workflows, and access administrative tools. Biopharmaceutical companies, IVD firms, and academic institutions purchase access to the platform’s data and services to accelerate medical discovery and streamline procurement processes. The company’s functional areas—search, workflow, data, and administration and reporting—support these transactions through integrated administrative and compliance management for all users. The iSpecimen Marketplace platform serves biopharmaceutical companies, in vitro diagnostic (IVD) companies, and government/academic institutions by providing a centralized hub for biospecimen procurement. Healthcare providers supplying biospecimens use the platform to list their collections, while researchers from the target sectors access the data for their studies. The platform’s de-identified healthcare data, compiled from healthcare supply partners, is a key asset that drives transactions. Administrative and reporting functions within the platform streamline operations for both suppliers and researchers, reducing manual effort and improving compliance. iSpecimen, Inc. monetizes its platform by facilitating connections between biospecimen suppliers and researchers across biopharmaceutical, IVD, and academic sectors. The company’s revenue comes from transactions and services provided through the iSpecimen Marketplace, which includes search capabilities, workflow management, data access, and administrative support. Healthcare supply partners contribute de-identified healthcare data to the platform, which researchers use to identify and procure necessary biospecimens for medical research and development. iSpecimen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about iSpecimen stock

Long-Term Debt of iSpecimen is 3.42 M USD in 2021.

Long-Term Debt of iSpecimen changed from 178,899.00 USD to 3.42 M USD, representing a 1,813.16% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt iSpecimen since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's iSpecimen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — iSpecimen

All Key Metrics — iSpecimen